Abstract
Recent years have witnessed a trend to search for the possibility of repurposing widely prescribed drugs in the field of oncology. This applies to thiazolidinediones, peroxisome proliferator-activated receptor-gamma (PPARγ) receptor agonists, the anti-diabetic drugs which showed antitumor activities and evidence for the induction of breast cancer cells differentiation. We aimed to investigate the potential of repurposing a PPARγ ligand, rosiglitazone (RGZ), in combination with either of two chemotherapeutic agents, doxorubicin (Dox) or cisplatin (Cis) for the in vitro treatment of breast cancer cell line, MCF-7.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
